Publication date: Jul 05, 2025
TOPLINE:Augmenting antidepressant treatment with pramipexole led to a significant reduction in symptoms relative to placebo in treatment-resistant major depressive disorder (MDD) at 12 weeks, a trial found. Several authors reported having financial ties with various organisations, pharmaceutical companies, and research councils, with some being employed previously or holding shares in industry. It was published online on June 29 in The Lancet Psychiatry. LIMITATIONS:Functional unmasking occurred during the study, potentially leading to expectancy effects. Details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
| Concepts | Keywords |
|---|---|
| Antipsychotics | Antidepressant |
| June | Depression |
| Remission | Group |
| Sr16 | Higher |
| Women | Placebo |
| Pramipexole | |
| Reduction | |
| Relative | |
| Resistant | |
| Score | |
| Symptoms | |
| Treatment | |
| Trial | |
| Week | |
| Weeks |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | major depressive disorder |
| disease | MESH | psychosis |
| disease | MESH | bipolar disorder |
| disease | MESH | Depression |
| drug | DRUGBANK | Pramipexole |